

# Brian W Ogilvie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1236130/publications.pdf>

Version: 2024-02-01

18  
papers

1,011  
citations

623188

14  
h-index

839053

18  
g-index

22  
all docs

22  
docs citations

22  
times ranked

1016  
citing authors

#	ARTICLE	IF	CITATIONS
1	GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS. <i>Drug Metabolism and Disposition</i> , 2006, 34, 191-197.	1.7	306
2	Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. <i>Drug Metabolism and Disposition</i> , 2016, 44, 453-459.	1.7	101
3	The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel. <i>Drug Metabolism and Disposition</i> , 2011, 39, 2020-2033.	1.7	90
4	Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1031-1038.	1.7	87
5	System-Dependent Outcomes during the Evaluation of Drug Candidates as Inhibitors of Cytochrome P450 (CYP) and Uridine Diphosphate Glucuronosyltransferase (UGT) Enzymes: Human Hepatocytes versus Liver Microsomes versus Recombinant Enzymes. <i>Drug Metabolism and Pharmacokinetics</i> , 2010, 25, 16-27.	1.1	68
6	An Evaluation of the Dilution Method for Identifying Metabolism-Dependent Inhibitors of Cytochrome P450 Enzymes. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1370-1387.	1.7	60
7	In Vitro Inhibition and Induction of Human Liver Cytochrome P450 Enzymes by Milnacipran. <i>Drug Metabolism and Disposition</i> , 2009, 37, 2045-2054.	1.7	58
8	The Reliability of Estimating $K_i$ Values for Direct, Reversible Inhibition of Cytochrome P450 Enzymes from Corresponding $IC_{50}$ Values: A Retrospective Analysis of 343 Experiments. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1744-1750.	1.7	40
9	Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416. <i>Toxicology in Vitro</i> , 2006, 20, 154-162.	1.1	37
10	Construction of Triple-Transfected Cells [Organic Anion-Transporting Polypeptide (OATP) 1B1/Multidrug Resistance-Associated Protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for Analysis of the Sinusoidal Function of MRP3 and MRP4. <i>Drug Metabolism and Disposition</i> , 2009, 37, 2103-2111.	1.7	35
11	An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1066-1074.	1.7	18
12	An in Vitro Evaluation of the Victim and Perpetrator Potential of the Anticancer Agent Laromustine (VNP40101M), Based on Reaction Phenotyping and Inhibition and Induction of Cytochrome P450 Enzymes. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1922-1930.	1.7	17
13	On the Mechanism of Hepatocarcinogenesis of Benzodiazepines: Evidence that Diazepam and Oxazepam are CYP2B Inducers in Rats, and both CYP2B and CYP4A Inducers in Mice. <i>Drug Metabolism Reviews</i> , 2006, 38, 235-259.	1.5	16
14	Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1004-1011.	1.0	15
15	In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions. <i>Pharmacology Research and Perspectives</i> , 2022, 10, .	1.1	9
16	In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions. <i>Pharmacology Research and Perspectives</i> , 2022, 10, .	1.1	8
17	Use of Enzyme Inhibitors to Evaluate the Conversion Pathways of Ester and Amide Prodrugs: A Case Study Example with the Prodrug Ceftobiprole Medocaril. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 1242-1252.	1.6	6
18	Effects of monocyte chemoattractant protein-1, macrophage inflammatory protein-1 $\alpha$ , and interferon-2a on P450 enzymes in human hepatocytes in vitro. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00551.	1.1	4